135159-51-2
135159-51-2 結構式
基本信息
鹽酸沙格雷酯
(+/-)-2-(二甲胺基)-1-{[2-(3-甲氧基苯基)苯氧基]甲基}乙基丁二酸單酯鹽酸鹽
SARPOGRELATE HCL
SARPOGRELATE HYDROCHLORIDE
Anplag
Butanedioic acid, mono[2-(dimethylamino)-1-[[2-[2-(3-methoxyphenyl)ethyl]phenoxy]methyl]ethyl] ester, hydrochloride (9CI)
Butanedioic acid, mono[2-(dimethylamino)-1-[[2-[2-(3-methoxyphenyl)ethyl]phenoxy]methyl]ethyl] ester, hydrochloride, (+-)-
MCI 9042
(+/-)-2-(Dimethylamino)-1-{[o-(m-methoxyphenethyl)phenoxy]methyl}ethyl hydrogen succinate hydrochloride
(+/-)-2-(Dimethylamino)-1-{[o-(m-methoxyphenethyl)phenoxy]methyl}ethyl hydrogen succinate hydrochloride
物理化學性質
制備方法
108-30-5
135963-42-7
135159-51-2
1. 將1-二甲氨基-3-[2-[2-(3-甲氧基苯基)乙基]苯氧基]-2-丙醇（29.8g，0.090mol）和琥珀酸酐（11.3g，0.113mol）溶解于丙酮（200ml）中。2. 加熱混合物至回流狀態(tài)，維持反應6小時。3. 反應完成后，將混合物置于冰浴中冷卻至0~5℃。4. 向冷卻的混合物中緩慢通入干燥的氯化氫氣體，調節(jié)pH值至1~2，此時有白色固體析出。5. 緩慢升溫至室溫，繼續(xù)攪拌8小時以確保反應完全。6. 過濾收集白色固體，干燥后使用丙酮進行重結晶。7. 最終得到白色固體鹽酸沙格雷酯（38.8g，收率92.5%），經(jīng)檢測純度為99.8%。
參考文獻：
[1] Patent: CN103965063, 2016, B. Location in patent: Paragraph 0019; 0023; 0027
常見問題列表
| Target | Value |
|
5-HT2A
(Cell-free) | 0.2 nM(Kd) |
|
5-HT2C
(Cell-free) | 1.1 nM(Kd) |
|
5-HT2B
(Cell-free) | 2.1 nM(Ki) |
|
5-HT2B
(Cell-free) | 2.1 nM(Kd) |
Sarpogrelate is selective for 5-HT
2
(pK
i
=7.54) over 5-HT
1
(pK
i
=4.58), α
1
-, α
2
-, and β-adrenergic (pK
i
=3.17-6.19), and muscarinic receptors (pK
i
=4.39).
Sarpogrelate (10 μM) significantly reduces the number of platelet-rich plasma (PRP)-induced THP-1 cell that adheres to human umbilical vein endothelial cells (HUVECs).
Sarpogrelate (10 μM) significantly reduces the expression of PRP-induced E-selectin in HUVECs.
Sarpogrelate (5 mg/kg; i.p. daily for 4 weeks) inhibits HFFD-induced obesity and decreases leukocyte-endothelial interactions in mice.
| Animal Model: | Male C57BL/6 mice (7 weeks old) are fed normal chow (NC) or a high-fat diet with 30% fructose in the drinking water (HFFD) |
| Dosage: | 5 mg/kg |
| Administration: | I.p. daily for 4 weeks |
| Result: |
Prevented the HFFD-induced increases of the body weight, visceral fat weight, and serum monocyte chemoattractant protein-1 levels.
Decreased leukocyte-endothelial interactions and serum monocyte chemoattractant protein-1 (MCP-1) level. |